Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22674287 | 1.00 | DRD4 (0.49) | DRD4HRH2SIGMAR1KDM4EPTGIR | |
| SCHEMBL22674824 | 1.00 | DRD4 (0.49) | DRD4HRH2SIGMAR1KDM4EPTGIR | |
| SCHEMBL29533955 | 1.00 | DRD4 (0.49) | DRD4HRH2SIGMAR1KDM4EPTGIR | |
| SCHEMBL12951976 | 0.83 | SIGMAR1 (0.55) | DRD4HRH2SIGMAR1KDM4EPTGIR | |
| SCHEMBL493570 | 0.79 | SIGMAR1 (0.58) | SIGMAR1PTGIRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13726456 | 0.79 | SIGMAR1 (0.57) | DRD4HRH2SIGMAR1KDM4EPTGIR | |
| SCHEMBL22488321 | 0.77 | ALDH1A1 (0.57) | DRD4SIGMAR1KDM4ESMN1; SMN2SLC18A3 | |
| SCHEMBL22488317 | 0.77 | ALDH1A1 (0.57) | DRD4SIGMAR1KDM4ESMN1; SMN2SLC18A3 | |
| SCHEMBL13650590 | 0.77 | ALDH1A1 (0.57) | DRD4SIGMAR1KDM4ESMN1; SMN2SLC18A3 | |
| SCHEMBL14198701 | 0.77 | KDM4E (0.57) | DRD4HRH2SIGMAR1KDM4EPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242886-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2022-08-04 | — | — | US | disclosed |
| EP-3969458-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210188879-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2021-06-24 | — | — | US | disclosed |
| WO-2020232470-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188879-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | DRD4 3942/4885HRH2 881/4885SIGMAR1 3466/4885 |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | DRD4 3942/4885HRH2 881/4885SIGMAR1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.